Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Disease × Capecitabine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 31 Breast Neoplasms 28 Pancreatic Neoplasms 20 Neoplasm Metastasis 16 Rectal Neoplasms 14 Stomach Neoplasms 13 Neoplasms 12 Esophageal Neoplasms 8 Triple Negative Breast Neoplasms 6 Colorectal Cancer Metastatic 6 Colonic Neoplasms 6 Brain Neoplasms 4 Adenocarcinoma 4 Head and Neck Neoplasms 3 Carcinoma, Non-Small-Cell Lung 3 Bile Duct Neoplasms 3 Advanced Solid Tumors 3 Squamous Cell Carcinoma of Head and Neck 2 Parkinson Disease 4, Autosomal Dominant Lewy Body 2 Lymphoma, Non-Hodgkin 2 Liver Neoplasms 2 Diabetes Mellitus, Insulin-Dependent, 12 2 Cholangiocarcinoma 2 Carcinoma, Renal Cell 2 Carcinoma, Hepatocellular 2 Breast Neoplasms, Male 2 Biliary Tract Neoplasms 2 Adenocarcinoma Of Esophagus 2 Waldenstrom Macroglobulinemia 1 Urinary Bladder Neoplasms 1

Interventions

carfilzomib 2 Dexamethasone 2 Cyclophosphamide 2 tivozanib 1 tislelizumab 1 pembrolizumab 1 neratinib 1 Nivolumab 1 Interleukin-15 1 Gemcitabine 1 Erlotinib Hydrochloride 1 Cisplatin 1 Capecitabine 1 Calcium Dobesilate 1 Bevacizumab 1 Albumin-Bound Paclitaxel 1 3-(1-benzenesulfonyl-2,3-dihydro-1H-indol-5-yl)-N-hydroxyacrylamide 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01730222 2017-09-01

PACT-19

IRCCS San Raffaele

Phase 1/2 Completed

Gastrointestinal

Disease, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡